Are there scenarios where you would still prefer adjuvant nivolumab based on known pathologic risk over using perioperative durvalumab for patients with muscle invasive bladder cancer?
Are there any subgroups which can predict specific benefit (or lack thereof) such as patients with residual disease or PD-L1 overexpression?
Community PollStarted
For which patient scenarios, if any, would you use neoadjuvant chemotherapy alone for muscle-invasive urothelial cancer, and wait to use IO adjuvantly?
38 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of California San Francisco
Answered on
Adjuvant nivolumab can still be considered for patients who fit the criteria for CheckMate 274, which led to the approval of this regimen. Specifically, this refers to patients who have not had perioperative chemotherapy and have high-risk disease at the time of radical cystectomy (≥pT3N0) or patien...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Mayo Clinic Comprehensive Cancer Center
Answered on
Perhaps for patients with lower clinical risks, cT2, cN0, I might consider neoadjuvant chemotherapy alone, and decide on adjuvant nivolumab accordingly based on the final pathologic stage. This is especially if I am concerned about the immunologic side effects by adding immunotherapy on top of chemo...
Join for free or sign in to see the full answer